Osteoinduction by Ex Vivo Nonviral Bone Morphogenetic Protein Gene Delivery Is Independent of Cell Type.

Ex vivo nonviral gene delivery of bone inductive factors has the potential to heal bone defects. Due to their inherent role in new bone formation, multipotent stromal cells (MSCs) have been studied as the primary target cell for gene delivery in a preclinical setting. The relative contribution of autocrine and paracrine mechanisms, and the need of osteogenic cells, remains unclear. This study investigates the contribution of MSCs as producer of transgenic bone morphogenetic proteins (BMPs) and to what extent the seeded MSCs participate in actual osteogenesis. Rat-derived MSCs or fibroblasts (FBs) were cotransfected with pBMP-2 and pBMP-6 or pBMP-7 via nucleofection. The bioactivity of BMP products was shown through in vitro osteogenic differentiation assays. To investigate their role in new bone formation, transfected cells were seeded on ceramic scaffolds and implanted subcutaneously in rats. Bone formation was assessed by histomorphometry after 8 weeks. As a proof of principle, we also investigated the suitability of bone marrow-derived mononuclear cells and the stromal vascular fraction isolated from adipose tissue for a one-stage gene delivery strategy. Bone formation was induced in all conditions containing cells overexpressing BMP heterodimers. Constructs seeded with FBs transfected with BMP-2/6 and MSCs transfected with BMP-2/6 showed comparable bone volumes, both significantly higher than controls. Single-stage gene delivery proved possible and resulted in some bone formation. We conclude that bone formation as a result of ex vivo BMP gene delivery can be achieved even without direct osteogenic potential of the transfected cell type, suggesting that transfected cells mainly function as a production facility for osteoinductive proteins. In addition, single-stage transfection and reimplantation of cells appeared feasible, thus facilitating future clinical translation of the method.

[1]  N. Hawkes.  Gene therapy trial for cystic fibrosis shows modest benefits , 2015, BMJ : British Medical Journal.

[2]  E. Rosenthal,et al.  Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Johnny Huard,et al.  Gene therapy approaches to regenerating the musculoskeletal system , 2015, Nature Reviews Rheumatology.

[4]  D. Rowe,et al.  The role of transduced bone marrow cells overexpressing BMP-2 in healing critical-sized defects in a mouse femur , 2015, Gene Therapy.

[5]  M. Lee,et al.  A Multicenter, Single-Blind, Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of a Cell-Mediated Gene Therapy in Degenerative Knee Arthritis Patients. , 2015, Human gene therapy. Clinical development.

[6]  W. Grayson,et al.  Stromal cells and stem cells in clinical bone regeneration , 2015, Nature Reviews Endocrinology.

[7]  J. Grieger,et al.  Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial , 2014, Human gene therapy.

[8]  Eric Meadows,et al.  A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  Megan Cully.  Trial watch: Self-inactivating gene-therapy vector alleviates safety concerns , 2014, Nature Reviews Drug Discovery.

[10]  W. Hauswirth,et al.  Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial. , 2014, JAMA ophthalmology.

[11]  W. Feuer,et al.  Trial end points and natural history in patients with G11778A Leber hereditary optic neuropathy : preparation for gene therapy clinical trial. , 2014, JAMA ophthalmology.

[12]  D. Gaudet,et al.  Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. , 2014, Human gene therapy.

[13]  G. Felker,et al.  Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). , 2014, JACC. Heart failure.

[14]  L. KaufmanHoward,et al.  Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules. , 2014 .

[15]  M. Kassem,et al.  Concise Review: Bridging the Gap: Bone Regeneration Using Skeletal Stem Cell‐Based Strategies—Where Are We Now? , 2014, Stem cells.

[16]  Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (GENEGRAFT). , 2014, Human gene therapy. Clinical development.

[17]  Wouter J A Dhert,et al.  Porous bioprinted constructs in BMP-2 non-viral gene therapy for bone tissue engineering. , 2013, Journal of materials chemistry. B.

[18]  A. Gee.  How to design a cell or gene therapy clinical trial: advice from the FDA. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  Monica Hoyos Flight.  Trial watch: Clinical trial boost for lentiviral gene therapy , 2013, Nature Reviews Drug Discovery.

[20]  P. Lowenstein,et al.  Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma. , 2013, Toxicology and applied pharmacology.

[21]  M. S. Halbreiner,et al.  Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease. , 2013, Human gene therapy.

[22]  Karine Tremblay,et al.  Efficacy and long term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open label trial , 2012, Gene Therapy.

[23]  W. Tawackoli,et al.  BMP-6 is more efficient in bone formation than BMP-2 when overexpressed in mesenchymal stem cells , 2012, Gene Therapy.

[24]  H. Petite,et al.  Ischemia is the prime but not the only cause of human multipotent stromal cell death in tissue-engineered constructs in vivo. , 2012, Tissue engineering. Part A.

[25]  Z. Kmietowicz.  Trial is started to see whether gene therapy can improve lung function in cystic fibrosis , 2012, BMJ : British Medical Journal.

[26]  S. Gambhir,et al.  "Same day" ex-vivo regional gene therapy: a novel strategy to enhance bone repair. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  Wouter J A Dhert,et al.  Luciferase labeling for multipotent stromal cell tracking in spinal fusion versus ectopic bone tissue engineering in mice and rats. , 2010, Tissue engineering. Part A.

[28]  Wouter J A Dhert,et al.  Use of fluorochrome labels in in vivo bone tissue engineering research. , 2010, Tissue engineering. Part B, Reviews.

[29]  J. Miyazaki,et al.  Simple strategy for bone regeneration with a BMP-2/7 gene expression cassette vector. , 2009, Biochemical and biophysical research communications.

[30]  T. Miyamae,et al.  Interleukin-6 inhibits early differentiation of ATDC5 chondrogenic progenitor cells. , 2009, Cytokine.

[31]  Yinghua Su,et al.  VEGF Gene Therapy Fails to Improve Perfusion of Ischemic Myocardium in Patients With Advanced Coronary Disease: Results of the NORTHERN Trial. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  G. Pelled,et al.  Nonvirally Engineered Porcine Adipose Tissue‐Derived Stem Cells: Use in Posterior Spinal Fusion , 2008, Stem cells.

[33]  J. Klein-Nulend,et al.  Stem cells from adipose tissue allow challenging new concepts for regenerative medicine. , 2007, Tissue engineering.

[34]  M. Liebergall,et al.  Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue regeneration. , 2006, Tissue engineering.

[35]  A. Hagenbeek,et al.  Genetic marking with the ΔLNGFR‐gene for tracing goat cells in bone tissue engineering , 2004 .

[36]  A. Davis,et al.  Osteoinduction by ex vivo adenovirus-mediated BMP2 delivery is independent of cell type , 2003, Gene Therapy.

[37]  R. Rutherford,et al.  Gene therapy-directed osteogenesis: BMP-7-transduced human fibroblasts form bone in vivo. , 2000, Human gene therapy.